Matches in Wikidata for { <http://www.wikidata.org/entity/Q92961461> ?p ?o ?g. }
Showing items 1 to 46 of
46
with 100 items per page.
- Q92961461 description "article scientifique publié en 2019" @default.
- Q92961461 description "artículu científicu espublizáu en xunu de 2019" @default.
- Q92961461 description "scientific article published on 13 June 2019" @default.
- Q92961461 description "wetenschappelijk artikel" @default.
- Q92961461 description "наукова стаття, опублікована 13 червня 2019" @default.
- Q92961461 name "Comparative evaluation of the new GRPR-antagonist 111 In-SB9 and 111 In-AMBA in prostate cancer models: Implications of in vivo stability" @default.
- Q92961461 name "Comparative evaluation of the new GRPR-antagonist 111 In-SB9 and 111 In-AMBA in prostate cancer models: Implications of in vivo stability" @default.
- Q92961461 type Item @default.
- Q92961461 label "Comparative evaluation of the new GRPR-antagonist 111 In-SB9 and 111 In-AMBA in prostate cancer models: Implications of in vivo stability" @default.
- Q92961461 label "Comparative evaluation of the new GRPR-antagonist 111 In-SB9 and 111 In-AMBA in prostate cancer models: Implications of in vivo stability" @default.
- Q92961461 prefLabel "Comparative evaluation of the new GRPR-antagonist 111 In-SB9 and 111 In-AMBA in prostate cancer models: Implications of in vivo stability" @default.
- Q92961461 prefLabel "Comparative evaluation of the new GRPR-antagonist 111 In-SB9 and 111 In-AMBA in prostate cancer models: Implications of in vivo stability" @default.
- Q92961461 P1433 Q92961461-3746E063-8C99-4781-A37A-4ECE0DF5F4BB @default.
- Q92961461 P1476 Q92961461-612268A9-A814-458D-AE91-59035683B3A4 @default.
- Q92961461 P2093 Q92961461-16C3C4BF-4BEF-4F07-A9F4-1B8CAE945D72 @default.
- Q92961461 P2093 Q92961461-893EBB23-FE65-48F3-A41A-C17734F8A396 @default.
- Q92961461 P2093 Q92961461-9B3BB3B6-D123-474D-8019-74F6D0B7F4FA @default.
- Q92961461 P2093 Q92961461-D8B18C1B-DCD4-417C-AEDF-8BCEBA02A546 @default.
- Q92961461 P304 Q92961461-940B2894-2DFC-4DE2-B7DC-6C4B40E6E330 @default.
- Q92961461 P31 Q92961461-29A9A4AF-3E87-431A-A379-CEB0F887A5F8 @default.
- Q92961461 P356 Q92961461-FCD48D96-BDD6-4170-8838-B9444E4043C8 @default.
- Q92961461 P433 Q92961461-14C19271-5A9D-4EB8-95AF-FB51B7DEB97E @default.
- Q92961461 P478 Q92961461-38D8A47F-E07B-4E18-B775-C24FC2349EB8 @default.
- Q92961461 P50 Q92961461-0BB89FDA-C30B-49C1-A764-0282BCA9BBF1 @default.
- Q92961461 P50 Q92961461-78C43775-8BE8-4462-87C0-EE19F179A36F @default.
- Q92961461 P50 Q92961461-884D0C0B-5F62-4CFE-A15F-6990C90B2B61 @default.
- Q92961461 P577 Q92961461-F010C0F9-3319-4CF3-9CE5-940DE3404E54 @default.
- Q92961461 P698 Q92961461-EB772ACB-D91D-4CD2-A3A3-89E0261C5B33 @default.
- Q92961461 P356 JLCR.3733 @default.
- Q92961461 P698 30963606 @default.
- Q92961461 P1433 Q3186923 @default.
- Q92961461 P1476 "Comparative evaluation of the new GRPR-antagonist 111 In-SB9 and 111 In-AMBA in prostate cancer models: Implications of in vivo stability" @default.
- Q92961461 P2093 "Aikaterini Kaloudi" @default.
- Q92961461 P2093 "Emmanouil Lymperis" @default.
- Q92961461 P2093 "Eric P Krenning" @default.
- Q92961461 P2093 "Marion de Jong" @default.
- Q92961461 P304 "646-655" @default.
- Q92961461 P31 Q13442814 @default.
- Q92961461 P356 "10.1002/JLCR.3733" @default.
- Q92961461 P433 "10" @default.
- Q92961461 P478 "62" @default.
- Q92961461 P50 Q87419950 @default.
- Q92961461 P50 Q88002174 @default.
- Q92961461 P50 Q89254621 @default.
- Q92961461 P577 "2019-06-13T00:00:00Z" @default.
- Q92961461 P698 "30963606" @default.